ABBOTT PARK, Ill., March 29, 2018 — Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New York Heart Association (NYHA) Class II – IV heart failure.

The YMCA and American Heart Association (AHA) are launching a collaborative effort this spring to help combat hypertension. Through the new partnership, clinics participating in the AHA and American Medical Association’s national Target: BP initiative can refer patients to the YMCA for free support in learning how to self-monitor their blood pressure.

Bioprosthetic heart valves used in surgical aortic valve replacement (SAVR) procedures in the early 2000s demonstrated “satisfactory” durability, according to a single-center study published in the Journal of the American College of Cardiology.

Damaged tissue resulting from myocardial infarction could one day be repaired with specially engineered patches seeded with cardiac cells to encourage the regeneration of healthy cells in the muscle.

A high dose of oral ibuprofen appeared to be the best option for closing patent ductus arteriosus (PDA) in a meta-analysis of 4,802 preterm infants, researchers reported in JAMA.

Foreign-born adults living in the United States have a lower incidence of coronary heart disease (CHD) and stroke than U.S.–born adults, according to new findings by the Centers for Disease Control and Prevention, published in the Journal of the American Heart Association.

The Dexcom G6 continuous glucose monitoring (CGM) system received FDA marketing approval March 27, the agency announced. This is the first system permitted by the FDA to be used in an “integrated” fashion alongside other diabetes management devices, including automatic insulin dosing systems, insulin pumps and blood glucose meters.

Santa Monica, CA, March 28, 2018 — BioSig Technologies, Inc. (OTCQB: BSGM) announced that the Company has filed 510(k) application to the U.S. Food and Drug Administration (FDA) for its first product, PURE EP(TM) System.